La talidomide nel trattamento delle connettiviti e delle vasculiti

Translated title of the contribution: Thalidomide in treatment of connective diseases and vasculities

N. Maruotti, F. P. Cantatore, D. Ribatti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T-helper 2 cells. Thalidomide also inhibits proliferation of stimulated T-cells and leukocyte chemotaxis. It modifies a number of integrin receptors and other leukocytic surface receptors and down-modulates cell-adhesion molecules involved in leukocyte migration. It has been demonstrated that thalidomide inhibits TNFα, IL-5, IL-6, IL-8, IL-12 production and increases production of IL-2, IL-10 and INFγ. Moreover thalidomide plays an important role in inhibition of VEGF and FGF-2 mediated angiogenesis. Although the exact mechanism of action is not fully understood and only limited treatment opinions exist, thalidomide plays a role also in connective diseases and vasculities. Thalidomide has been seen efficacious in the treatment of cutaneous disorders in patients with systemic lupus erythematosus and in mucocutaneous disease in Behçet's disease with a not dose-dependent response, even if it should be restricted to selected patients because of its important side effects.

Original languageItalian
Pages (from-to)187-190
Number of pages4
JournalReumatismo
Volume58
Issue number3
Publication statusPublished - 2006

Fingerprint

Thalidomide
T-Lymphocytes
Therapeutics
Leukocyte Chemotaxis
Th2 Cells
Angiogenesis Inhibitors
Interleukin-5
Cell Adhesion Molecules
Fibroblast Growth Factor 2
Interleukin-12
Interleukin-8
Integrins
Natural Killer Cells
Systemic Lupus Erythematosus
Interleukin-10
Vascular Endothelial Growth Factor A
Interleukin-2
Interleukin-6
Leukocytes
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Rheumatology

Cite this

Maruotti, N., Cantatore, F. P., & Ribatti, D. (2006). La talidomide nel trattamento delle connettiviti e delle vasculiti. Reumatismo, 58(3), 187-190.

La talidomide nel trattamento delle connettiviti e delle vasculiti. / Maruotti, N.; Cantatore, F. P.; Ribatti, D.

In: Reumatismo, Vol. 58, No. 3, 2006, p. 187-190.

Research output: Contribution to journalArticle

Maruotti, N, Cantatore, FP & Ribatti, D 2006, 'La talidomide nel trattamento delle connettiviti e delle vasculiti', Reumatismo, vol. 58, no. 3, pp. 187-190.
Maruotti N, Cantatore FP, Ribatti D. La talidomide nel trattamento delle connettiviti e delle vasculiti. Reumatismo. 2006;58(3):187-190.
Maruotti, N. ; Cantatore, F. P. ; Ribatti, D. / La talidomide nel trattamento delle connettiviti e delle vasculiti. In: Reumatismo. 2006 ; Vol. 58, No. 3. pp. 187-190.
@article{dfde9fff6af74caa9ce6304ac068945e,
title = "La talidomide nel trattamento delle connettiviti e delle vasculiti",
abstract = "Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T-helper 2 cells. Thalidomide also inhibits proliferation of stimulated T-cells and leukocyte chemotaxis. It modifies a number of integrin receptors and other leukocytic surface receptors and down-modulates cell-adhesion molecules involved in leukocyte migration. It has been demonstrated that thalidomide inhibits TNFα, IL-5, IL-6, IL-8, IL-12 production and increases production of IL-2, IL-10 and INFγ. Moreover thalidomide plays an important role in inhibition of VEGF and FGF-2 mediated angiogenesis. Although the exact mechanism of action is not fully understood and only limited treatment opinions exist, thalidomide plays a role also in connective diseases and vasculities. Thalidomide has been seen efficacious in the treatment of cutaneous disorders in patients with systemic lupus erythematosus and in mucocutaneous disease in Beh{\cc}et's disease with a not dose-dependent response, even if it should be restricted to selected patients because of its important side effects.",
keywords = "Beh{\cc}et's disease, Systemic lupus erythematosus, Thalidomide",
author = "N. Maruotti and Cantatore, {F. P.} and D. Ribatti",
year = "2006",
language = "Italian",
volume = "58",
pages = "187--190",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "3",

}

TY - JOUR

T1 - La talidomide nel trattamento delle connettiviti e delle vasculiti

AU - Maruotti, N.

AU - Cantatore, F. P.

AU - Ribatti, D.

PY - 2006

Y1 - 2006

N2 - Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T-helper 2 cells. Thalidomide also inhibits proliferation of stimulated T-cells and leukocyte chemotaxis. It modifies a number of integrin receptors and other leukocytic surface receptors and down-modulates cell-adhesion molecules involved in leukocyte migration. It has been demonstrated that thalidomide inhibits TNFα, IL-5, IL-6, IL-8, IL-12 production and increases production of IL-2, IL-10 and INFγ. Moreover thalidomide plays an important role in inhibition of VEGF and FGF-2 mediated angiogenesis. Although the exact mechanism of action is not fully understood and only limited treatment opinions exist, thalidomide plays a role also in connective diseases and vasculities. Thalidomide has been seen efficacious in the treatment of cutaneous disorders in patients with systemic lupus erythematosus and in mucocutaneous disease in Behçet's disease with a not dose-dependent response, even if it should be restricted to selected patients because of its important side effects.

AB - Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T-helper 2 cells. Thalidomide also inhibits proliferation of stimulated T-cells and leukocyte chemotaxis. It modifies a number of integrin receptors and other leukocytic surface receptors and down-modulates cell-adhesion molecules involved in leukocyte migration. It has been demonstrated that thalidomide inhibits TNFα, IL-5, IL-6, IL-8, IL-12 production and increases production of IL-2, IL-10 and INFγ. Moreover thalidomide plays an important role in inhibition of VEGF and FGF-2 mediated angiogenesis. Although the exact mechanism of action is not fully understood and only limited treatment opinions exist, thalidomide plays a role also in connective diseases and vasculities. Thalidomide has been seen efficacious in the treatment of cutaneous disorders in patients with systemic lupus erythematosus and in mucocutaneous disease in Behçet's disease with a not dose-dependent response, even if it should be restricted to selected patients because of its important side effects.

KW - Behçet's disease

KW - Systemic lupus erythematosus

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33749025817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749025817&partnerID=8YFLogxK

M3 - Articolo

C2 - 17013434

AN - SCOPUS:33749025817

VL - 58

SP - 187

EP - 190

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - 3

ER -